Royal Bank of Canada’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$439K Buy
24,261
+2,611
+12% +$49.8K ﹤0.01% 4236
2025
Q4
$471K Sell
21,650
-35,167
-62% -$1.01M ﹤0.01% 4212
2025
Q3
$1.85M Buy
56,817
+21,496
+61% +$794K ﹤0.01% 3465
2025
Q2
$1.25M Buy
35,321
+35,021
+11,674% +$1.13M ﹤0.01% 3703
2025
Q1
$10K Sell
300
-499
-62% -$17.9K ﹤0.01% 6158
2024
Q4
$26K Sell
799
-724
-48% -$30K ﹤0.01% 6002
2024
Q3
$74K Sell
1,523
-1,520
-50% -$81K ﹤0.01% 5516
2024
Q2
$135K Sell
3,043
-957
-24% -$44.1K ﹤0.01% 5067
2024
Q1
$224K Buy
4,000
+3,900
+3,900% +$235K ﹤0.01% 4596
2023
Q4
$6K Sell
100
-468
-82% -$29.7K ﹤0.01% 6620
2023
Q3
$38K Buy
568
+554
+3,957% +$38.5K ﹤0.01% 5923
2023
Q2
$1K Buy
+14
New +$915 ﹤0.01% 7024
2023
Q1
Sell
-18
Closed -$1K 7283
2022
Q4
$1K Hold
18
﹤0.01% 7044
2022
Q3
$1K Buy
+18
New +$845 ﹤0.01% 7212
2021
Q3
Sell
-41
Closed -$2K 7749
2021
Q2
$2K Buy
+41
New +$1.39K ﹤0.01% 7250

Other funds holding LEGN

Royal Bank of Canada's LEGN Position: Q1 2026 in Review

Royal Bank of Canada increased its Legend Biotech (LEGN) stake by 12% in Q1 2026, buying an estimated $49.8K and bringing the position to 24,261 shares worth $439K. The position accounts for ﹤0.01% of the portfolio, ranked #4236.

Royal Bank of Canada first reported a position in LEGN in Q2 2021 and has held it in 15 quarters since. The position peaked at $1.85M in Q3 2025. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Royal Bank of Canada held 24,261 shares of Legend Biotech worth $439K as of Q1 2026.
  • Royal Bank of Canada bought 2,611 Legend Biotech shares in Q1 2026, an estimated $49.8K.
  • Legend Biotech made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4236 holding.
  • Royal Bank of Canada first reported a position in Legend Biotech in Q2 2021 and has held it in 15 quarters since.
  • Royal Bank of Canada's Legend Biotech position peaked at $1.85M in Q3 2025.
  • 190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.